If you or someone you love has been told they have major depressive disorder, you may have questions — and you may also be carrying a heavy burden of misunderstanding. Depression is one of the most common and most misunderstood medical conditions in the world. It is not a character flaw. It is not laziness. It is a medical illness with identifiable changes in brain chemistry, brain structure, and genetic risk — and it deserves the same respect and treatment as any other serious health condition.
Here’s what science tells us.
What Major Depressive Disorder Actually Looks Like
Major depressive disorder (MDD) is more than just feeling sad. It is a clinical syndrome — a cluster of symptoms that persist for at least two weeks, occur nearly every day, and significantly impair a person’s ability to function at work, at home, and in relationships.
To be diagnosed with MDD, a person must experience at least five of the following symptoms, and at least one must be either persistent low mood or loss of interest/pleasure in activities they used to enjoy:
– Depressed mood most of the day (feeling sad, empty, or hopeless)
– Loss of interest or pleasure in nearly all activities (called anhedonia)
– Significant changes in weight or appetite (increase or decrease)
– Insomnia or sleeping too much
– Physical restlessness or feeling slowed down (observable by others)
– Fatigue or loss of energy
– Feelings of worthlessness or excessive guilt
– Difficulty thinking, concentrating, or making decisions
– Recurrent thoughts of death or suicide
Importantly, many people with depression don’t walk into a doctor’s office saying “I feel depressed.” Instead, they report fatigue, pain, trouble sleeping, or difficulty concentrating. In primary care clinics around the world, 45% to 95% of patients with major depression initially present with physical symptoms rather than emotional ones. This is one reason depression is frequently underdiagnosed.
Your Brain on Depression: It’s Not “All in Your Head” — It’s in Your Biology
One of the most persistent myths about depression is that it’s simply a matter of willpower or attitude. Decades of neuroscience research tell a very different story.
The brain chemistry of depression involves multiple neurotransmitter systems — the chemical messengers that allow brain cells to communicate with each other:
– Serotonin, norepinephrine, and dopamine — the monoamine neurotransmitters — have long been implicated in depression. Dysfunction in these systems affects mood regulation, motivation, pleasure, energy, and sleep. This is why many antidepressant medications work by increasing the availability of these chemicals in the brain.
– GABA and glutamate — the brain’s primary inhibitory and excitatory neurotransmitters — are also disrupted in depression. Research has found that people with depression have reduced GABA levels in the prefrontal cortex, a brain region critical for decision-making and emotional regulation. This finding has helped explain why newer treatments like ketamine, which targets the glutamate system, can produce rapid antidepressant effects.
But depression goes beyond neurotransmitters. Brain imaging studies have revealed measurable structural and functional changes in the brains of people with depression:
– The hippocampus (involved in memory and emotional processing) is consistently smaller in people with depression, and the degree of volume loss is related to the duration of untreated illness.
– The amygdala (the brain’s threat-detection center) shows increased activity, contributing to heightened anxiety and emotional reactivity.
– The prefrontal cortex (responsible for planning, decision-making, and regulating emotions) shows reduced activity and volume, impairing the brain’s ability to manage negative thoughts and feelings.
Additionally, chronic stress activates the body’s hypothalamic-pituitary-adrenal (HPA) axis — the main stress response system — leading to elevated cortisol levels. Over time, this creates a state of chronic inflammation in the brain (neuroinflammation), which damages neurons, impairs the growth of new brain cells, and disrupts the very circuits that regulate mood. People with depression consistently show elevated levels of inflammatory markers like interleukin-6 (IL-6), interleukin-1ß, and tumor necrosis factor-alpha (TNF-a).
In other words, depression changes the brain — its chemistry, its structure, and its inflammatory state. These are not changes a person can simply “think” their way out of.
Genetics: Depression Runs in Families — and in DNA
If depression were simply a response to life circumstances, it wouldn’t cluster in families the way it does. But it does — and genetics is a major reason why.
Research consistently shows that 30% to 50% of the variation in risk for major depression is attributable to genetic factors. First-degree relatives of people with depression have
approximately three times the risk of developing the disorder compared to the general population.
Large-scale genetic studies have now identified over 243 risk locations (loci) in the human genome associated with depression, including genes that encode receptors for GABA and glutamate — the same neurotransmitter systems implicated in the brain chemistry of depression. Depression is what scientists call “highly polygenic,” meaning that hundreds or even thousands of small genetic variations each contribute a small amount of risk. No single gene causes depression, but the cumulative burden of these genetic variants — combined with environmental stressors — can tip the balance.
Importantly, the heritability of depression varies by subtype. More severe, recurrent, and early-onset forms of depression show higher heritability (up to 58%), while single-episode depression without psychiatric comorbidity shows lower heritability (around 30%). This means that the more severe the depression, the stronger the genetic contribution tends to be.
This genetic evidence reinforces a critical point: people don’t choose to be depressed any more than they choose to have diabetes or heart disease.
Depression Is Medical, Not Weakness
Despite everything science has shown us, stigma around depression persists. Many people feel embarrassed by a diagnosis of depression, worry about being seen as weak, or believe they should be able to “snap out of it.” This stigma is one of the biggest barriers to people getting the help they need.
Here are the facts:
– Depression is the leading cause of disability worldwide and affects an estimated 1 in 5 people over their lifetime.
– It involves measurable changes in brain structure, brain chemistry, the stress hormone system, and the immune system.
– It has a genetic basis comparable to many other common medical conditions.
– It worsens the outcomes of other chronic diseases, including heart disease, diabetes, and lung disease.
– It is treatable — but only if people seek and receive care.
A helpful way to think about it: just as a person with diabetes may need insulin to restore blood sugar levels to normal, a person with depression may need treatment to restore brain chemistry to a healthier state. Treatment isn’t fixing something that’s “broken” — it’s restoring something to normal.
When Standard Treatment Isn’t Enough: Treatment-Resistant Depression
For many people, the first antidepressant they try — combined with therapy and lifestyle changes — brings meaningful relief. But for a significant number, it doesn’t. When depression does not improve despite adequate trials of at least two different antidepressant medications (taken at the right dose, for the right duration, with good adherence), it is called treatment-resistant depression, or TRD.
Treatment-resistant depression is not rare. It is estimated that at least 30% of people with major depression meet this definition. These individuals tend to have a more severe course of illness, higher healthcare costs, and a significantly increased risk of suicide.
But treatment-resistant does not mean untreatable. There are several evidence-based options:
– Augmentation with a second-generation antipsychotic (such as aripiprazole, brexpiprazole, or quetiapine) added to an existing antidepressant
– Intranasal esketamine (Spravato), an FDA-approved treatment specifically for treatment-resistant depression, which works through the glutamate system and can produce rapid improvement
– Repetitive transcranial magnetic stimulation (TMS), a non-invasive brain stimulation technique that is FDA-approved for TRD
– Electroconvulsive therapy (ECT), one of the most effective treatments available for severe, treatment-resistant depression
– Psychotherapy added to medication, which can significantly improve outcomes even when medication alone has not been sufficient
– Intravenous ketamine, which has shown efficacy in TRD and works through different brain pathways than traditional antidepressants
If standard treatment isn’t working, the most important thing to know is this: there are more options. Talk to your provider about next steps. A referral to a psychiatrist who specializes in treatment-resistant depression can open doors to therapies that may make a real difference.
The Bottom Line
Depression is a medical condition rooted in biology — in your brain chemistry, your brain structure, your stress response system, your inflammatory pathways, and your DNA. It is not a personal failing. It is not something you caused, and it is not something you should have to face alone.
Whether you’re dealing with a first episode of depression or struggling with treatment resistance, effective help exists. The first step is understanding that what you’re experiencing is real, it’s medical, and it deserves treatment.
Looking Ahead
For some individuals, depression improves with therapy, medication, lifestyle changes, or a combination of treatments. But what happens when symptoms persist despite trying multiple approaches?
In our next blog post, we’ll explore treatment-resistant depression, a condition that affects many people living with Major Depressive Disorder. We’ll discuss how treatment-resistant depression is defined, why it can occur, and the advanced treatment options that may help when traditional therapies have not provided sufficient relief. Understanding these options can offer hope and help individuals recognize that ongoing symptoms do not mean recovery is out of reach.
